Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?-Reference-Cited by-同舟云学术

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

Published:2019-10-28 Issue:3 Volume:20 Page:879-883
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Nordness Mina F.¹^ORCID,Hamel Stephanie²,Godfrey Caroline M.¹,Shi Chanjuan³,Johnson Douglas B.⁴,Goff Laura W.⁴,O’Dell Heather¹,Perri Roman E.⁵,Alexopoulos Sophoclis P.¹

Affiliation:

1. Section of Surgical Sciences Department of Surgery Division of Hepatobiliary Surgery & Liver Transplantation Vanderbilt University Medical Center Nashville Tennessee

2. Department of Pharmaceutical Services Vanderbilt University Medical Center Nashville Tennessee

3. Department of Pathology Vanderbilt University Medical Center, Microbiology, Microbiology Nashville Tennessee

4. Department of Medicine Division of Hematology Oncology Vanderbilt University Medical Center Nashville Tennessee

5. Department of Medicine Division of Gastroenterology, Hepatology and Nutrition Vanderbilt University Medical Center Nashville Tennessee

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.15617

Reference20 articles.

1. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib. Accessed June 17 2019.

2. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

3. Cancer immunotherapy using checkpoint blockade

4. Immune‐related adverse events with immune checkpoint blockade: a comprehensive review;Michot JM;Eur J Cancer,1990

5. Immune Checkpoint Inhibitor Toxicity in 2018

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?;World Journal of Gastrointestinal Pharmacology and Therapeutics;2024-09-05

2. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study;Journal of Hepatology;2024-09

3. Current Trends in Hepatocellular Carcinoma Therapies in China;Digestive Disease Interventions;2024-08-26

4. Immunotherapy Prior to a Liver Transplant: Literature Review and a Case Report of Hepatocellular Carcinoma With BRCA1 Mutation;Innovative Medicine of Kuban;2024-08-23

5. Hepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation;Annals of Surgical Oncology;2024-08-22